Technical feasibility of sentinel lymph node biopsy in patients with ipsilateral breast tumor recurrence and previous axillary surgery

Akiko Matsumoto, Hiromitsu Jinno, Tetsuya Nakamura, Junichi Saito, Maiko Takahashi, Tetsu Hayashida, Kaori Kameyama, Yuukou Kitagawa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: The role of sentinel lymph node biopsy (SLNB) in patients with ipsilateral breast tumor recurrence (IBTR) remains to be elucidated. The aim of this study was to evaluate feasibility and validity of SLNB in patients with IBTR. Methods: A prospective database of 1172 patients with clinically node-negative breast cancer who underwent SLNB from January 2005 to December 2013 at Keio University Hospital was analyzed and 35 patients with IBTR underwent SLNB. Sentinel lymph nodes (SLNs) were detected using a combined method of blue dye and radioisotope or indocyanine green fluorescence in cases with failure of identification by blue dye and radioisotope. Results: Twenty-two patients had previous SLNB, eight had previous axillary lymph node dissection (ALND), and five had no previous axillary surgery. Overall, SLNs were successfully identified in 28 (80.0%) of 35 patients. The identification rate in patients with previous SLNB, ALND and no axillary surgery was 81.8% (18/22), 75% (6/8) and 80% (4/5), respectively (P = 0.52). Aberrant drainage outside the ipsilateral axilla was found more frequently in patients with previous ALND compared with SLNB and no axillary treatment (37.5% vs. 4.5% vs. 0%, P = 0.048). No axillary recurrence was observed after median follow-up of 40.3 months from the second surgery for IBTR. Conclusions: SLNB is a technically feasible and valid procedure for staging and treatment of regional lymph nodes in patients with IBTR.

Original languageEnglish
Article number2110
Pages (from-to)28-31
Number of pages4
JournalInternational Journal of Surgery
Volume22
DOIs
Publication statusPublished - 2015 Oct 1

Fingerprint

Sentinel Lymph Node Biopsy
Breast Neoplasms
Recurrence
Lymph Node Excision
Radioisotopes
Coloring Agents
Axilla
Indocyanine Green
Drainage
Fluorescence
Lymph Nodes
Databases

Keywords

  • Axillary lymph node dissection
  • Breast cancer
  • Ipsilateral breast tumor recurrence
  • Lymphatic mapping
  • Sentinel lymph node biopsy

ASJC Scopus subject areas

  • Surgery

Cite this

Technical feasibility of sentinel lymph node biopsy in patients with ipsilateral breast tumor recurrence and previous axillary surgery. / Matsumoto, Akiko; Jinno, Hiromitsu; Nakamura, Tetsuya; Saito, Junichi; Takahashi, Maiko; Hayashida, Tetsu; Kameyama, Kaori; Kitagawa, Yuukou.

In: International Journal of Surgery, Vol. 22, 2110, 01.10.2015, p. 28-31.

Research output: Contribution to journalArticle

@article{89f4b9f3b0f44cc5b141a60329f9405f,
title = "Technical feasibility of sentinel lymph node biopsy in patients with ipsilateral breast tumor recurrence and previous axillary surgery",
abstract = "Introduction: The role of sentinel lymph node biopsy (SLNB) in patients with ipsilateral breast tumor recurrence (IBTR) remains to be elucidated. The aim of this study was to evaluate feasibility and validity of SLNB in patients with IBTR. Methods: A prospective database of 1172 patients with clinically node-negative breast cancer who underwent SLNB from January 2005 to December 2013 at Keio University Hospital was analyzed and 35 patients with IBTR underwent SLNB. Sentinel lymph nodes (SLNs) were detected using a combined method of blue dye and radioisotope or indocyanine green fluorescence in cases with failure of identification by blue dye and radioisotope. Results: Twenty-two patients had previous SLNB, eight had previous axillary lymph node dissection (ALND), and five had no previous axillary surgery. Overall, SLNs were successfully identified in 28 (80.0{\%}) of 35 patients. The identification rate in patients with previous SLNB, ALND and no axillary surgery was 81.8{\%} (18/22), 75{\%} (6/8) and 80{\%} (4/5), respectively (P = 0.52). Aberrant drainage outside the ipsilateral axilla was found more frequently in patients with previous ALND compared with SLNB and no axillary treatment (37.5{\%} vs. 4.5{\%} vs. 0{\%}, P = 0.048). No axillary recurrence was observed after median follow-up of 40.3 months from the second surgery for IBTR. Conclusions: SLNB is a technically feasible and valid procedure for staging and treatment of regional lymph nodes in patients with IBTR.",
keywords = "Axillary lymph node dissection, Breast cancer, Ipsilateral breast tumor recurrence, Lymphatic mapping, Sentinel lymph node biopsy",
author = "Akiko Matsumoto and Hiromitsu Jinno and Tetsuya Nakamura and Junichi Saito and Maiko Takahashi and Tetsu Hayashida and Kaori Kameyama and Yuukou Kitagawa",
year = "2015",
month = "10",
day = "1",
doi = "10.1016/j.ijsu.2015.07.709",
language = "English",
volume = "22",
pages = "28--31",
journal = "International Journal of Surgery",
issn = "1743-9191",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Technical feasibility of sentinel lymph node biopsy in patients with ipsilateral breast tumor recurrence and previous axillary surgery

AU - Matsumoto, Akiko

AU - Jinno, Hiromitsu

AU - Nakamura, Tetsuya

AU - Saito, Junichi

AU - Takahashi, Maiko

AU - Hayashida, Tetsu

AU - Kameyama, Kaori

AU - Kitagawa, Yuukou

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Introduction: The role of sentinel lymph node biopsy (SLNB) in patients with ipsilateral breast tumor recurrence (IBTR) remains to be elucidated. The aim of this study was to evaluate feasibility and validity of SLNB in patients with IBTR. Methods: A prospective database of 1172 patients with clinically node-negative breast cancer who underwent SLNB from January 2005 to December 2013 at Keio University Hospital was analyzed and 35 patients with IBTR underwent SLNB. Sentinel lymph nodes (SLNs) were detected using a combined method of blue dye and radioisotope or indocyanine green fluorescence in cases with failure of identification by blue dye and radioisotope. Results: Twenty-two patients had previous SLNB, eight had previous axillary lymph node dissection (ALND), and five had no previous axillary surgery. Overall, SLNs were successfully identified in 28 (80.0%) of 35 patients. The identification rate in patients with previous SLNB, ALND and no axillary surgery was 81.8% (18/22), 75% (6/8) and 80% (4/5), respectively (P = 0.52). Aberrant drainage outside the ipsilateral axilla was found more frequently in patients with previous ALND compared with SLNB and no axillary treatment (37.5% vs. 4.5% vs. 0%, P = 0.048). No axillary recurrence was observed after median follow-up of 40.3 months from the second surgery for IBTR. Conclusions: SLNB is a technically feasible and valid procedure for staging and treatment of regional lymph nodes in patients with IBTR.

AB - Introduction: The role of sentinel lymph node biopsy (SLNB) in patients with ipsilateral breast tumor recurrence (IBTR) remains to be elucidated. The aim of this study was to evaluate feasibility and validity of SLNB in patients with IBTR. Methods: A prospective database of 1172 patients with clinically node-negative breast cancer who underwent SLNB from January 2005 to December 2013 at Keio University Hospital was analyzed and 35 patients with IBTR underwent SLNB. Sentinel lymph nodes (SLNs) were detected using a combined method of blue dye and radioisotope or indocyanine green fluorescence in cases with failure of identification by blue dye and radioisotope. Results: Twenty-two patients had previous SLNB, eight had previous axillary lymph node dissection (ALND), and five had no previous axillary surgery. Overall, SLNs were successfully identified in 28 (80.0%) of 35 patients. The identification rate in patients with previous SLNB, ALND and no axillary surgery was 81.8% (18/22), 75% (6/8) and 80% (4/5), respectively (P = 0.52). Aberrant drainage outside the ipsilateral axilla was found more frequently in patients with previous ALND compared with SLNB and no axillary treatment (37.5% vs. 4.5% vs. 0%, P = 0.048). No axillary recurrence was observed after median follow-up of 40.3 months from the second surgery for IBTR. Conclusions: SLNB is a technically feasible and valid procedure for staging and treatment of regional lymph nodes in patients with IBTR.

KW - Axillary lymph node dissection

KW - Breast cancer

KW - Ipsilateral breast tumor recurrence

KW - Lymphatic mapping

KW - Sentinel lymph node biopsy

UR - http://www.scopus.com/inward/record.url?scp=84943525579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943525579&partnerID=8YFLogxK

U2 - 10.1016/j.ijsu.2015.07.709

DO - 10.1016/j.ijsu.2015.07.709

M3 - Article

C2 - 26278666

AN - SCOPUS:84943525579

VL - 22

SP - 28

EP - 31

JO - International Journal of Surgery

JF - International Journal of Surgery

SN - 1743-9191

M1 - 2110

ER -